Altimmune 2025 Q3 Earnings Narrows Loss by 34.4% as Revenue Stabilizes

Altimmune (ALT) reported fiscal 2025 Q3 earnings on Nov 6, 2025, with stabilized revenue and improved losses. The company exceeded analyst expectations for both revenue and net income, driven by cost management and progress in its MASH/AUD programs. Management highlighted a 48-week IMPACT trial data release and an FDA End-of-Phase-2 meeting as key near-term milestones.

Revenue

, aligning with 2024 Q3 levels.

Earnings/Net Income

, . , . This marks a positive step in cost control, though losses persist.

Price Action

, .

Post-Earnings Price Action Review

Despite narrowing losses, the stock’s mixed short-term performance reflects investor caution ahead of key clinical milestones. , . .

CEO Commentary

Dr. emphasized progress toward a “major inflection point” for pemvidutide, including the 48-week IMPACT trial data and FDA alignment on Phase 3 design. New executives, including CMO Dr. Christophe Arbet-Engels and CCO Linda Richardson, were cited as strategic hires to accelerate development and commercialization.

Guidance

, , . Financially, , 2025, with no revenue guidance provided.

Additional News

. Key leadership additions, including a new Chief Medical Officer, , and Chief Legal Officer, were announced to strengthen its MASH and AUD programs. Additionally, the company amended its loan agreement with Hercules Capital, providing flexibility for future financing needs. These moves underscore Altimmune’s focus on advancing pemvidutide’s regulatory readiness amid a competitive MASH landscape.